jetcityimage/iStock Editorial via Getty Images
Chinese biotech Laekna Therapeutics on Wednesday announced a clinical collaboration with Eli Lilly (NYSE:LLY) to develop an obesity therapy that can avoid loss of muscle mass, a problem often linked to LLY’s weight loss therapy, tirzepatide.
Shanghai-based Laekna said the